Sotyktu

News

Dr Jörn Drappa, Alumis' chief medical officer

Alumis shoots up as its Sotyktu rival aces psoriasis trials

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.

News

Takeda plans filings for Sotyktu rival on new psoriasis data

Takeda intends to file for approval of its oral psoriasis therapy zasocitinib next year, with Bristol Myers Squibb's Sotyktu in its sights.

News

Person with psoriasis on hand and arm itches themself

BMS adds discounted psoriasis drug to its DTC channel

Bristol Myers Squibb expands its DTC sales in the US with the addition of psoriasis drug Sotyktu at an 80% discount for cash buyers.

News

J&J shows its confidence in oral IL-23 drug for psoriasis

J&J wants to turn the screw in the psoriasis market with a new head-to-head trial pitting oral IL-23 drug icotrokinra against Stelara.

News

BMS feels the pain of Revlimid erosion, cutting forecasts

Bristol-Myers Squibb is facing some serious near-term challenges as its top-selling drugs come under pressure, forcing it to slash its sales forecasts for the year.

News

BMS’ Sotyktu cleared for NHS use in psoriasis

Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales.

Alumis shoots up as its Sotyktu rival aces psoriasis trials

Takeda plans filings for Sotyktu rival on new psoriasis data

BMS adds discounted psoriasis drug to its DTC channel

J&J shows its confidence in oral IL-23 drug for psoriasis

BMS feels the pain of Revlimid erosion, cutting forecasts

BMS’ Sotyktu cleared for NHS use in psoriasis

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

Sotyktu

Editor's Picks